Pheochromocytoma/paraganglioma-associated cardiomyopathy.
dilated cardiomyopathy
hypertrophic cardiomyopathy
paraganglioma
pheochromocytoma
takotsubo cardiomyopathy
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
04
2023
accepted:
26
06
2023
medline:
1
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the sympathetic ganglia (10%). PPGL-associated cardiomyopathies can be chronic or acute, with takotsubo cardiomyopathy being the most often reported. These two types of PPGL-induced cardiomyopathy seem to have different pathophysiological backgrounds. Acute catecholaminergic stress inundates myocardial β-adrenoceptors and leads to left ventricle stunning and slight histological apoptosis. In chronic cardiomyopathy, prolonged catecholamine exposure leads to extended myocardial fibrosis, inflammation, and necrosis, and ultimately it causes dilated cardiomyopathy with a low ejection fraction. Sometimes, especially in cases associated with hypertension, hypertrophic cardiomyopathy can develop. The prognosis appears to be worse in chronic cases with a higher hospital mortality rate, higher cardiogenic shock rate at initial presentation, and lower left ventricular recovery rate after surgery. Therefore, establishing the correct diagnosis at an early stage of a PPGL is essential. This mini-review summarizes current data on pathophysiological pathways of cardiac damage caused by catecholamines, the clinical presentation of PPGL-induced cardiomyopathies, and discusses treatment options.
Identifiants
pubmed: 37522121
doi: 10.3389/fendo.2023.1204851
pmc: PMC10374018
doi:
Substances chimiques
Catecholamines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1204851Informations de copyright
Copyright © 2023 Szatko, Glinicki and Gietka-Czernel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Heart J. 2018 Jun 7;39(22):2047-2062
pubmed: 29850820
J Hypertens. 2011 Nov;29(11):2049-60
pubmed: 21826022
Postgrad Med J. 1984 Feb;60(700):111-5
pubmed: 6709540
Eur J Heart Fail. 2010 Jan;12(1):13-6
pubmed: 20023040
J Invasive Cardiol. 2014 Jun;26(6):E76-7
pubmed: 24907091
J Endocr Soc. 2022 Jan 14;6(2):bvac004
pubmed: 35128297
J Mol Cell Cardiol. 1985 Apr;17(4):291-306
pubmed: 3894676
Endocr Pract. 2017 Jun;23(6):690-704
pubmed: 28332883
Front Endocrinol (Lausanne). 2022 Jun 01;13:877341
pubmed: 35721724
Echo Res Pract. 2019 Aug 07;6(4):81-89
pubmed: 31516720
Front Endocrinol (Lausanne). 2022 Mar 08;13:853878
pubmed: 35355563
Eur Heart J Case Rep. 2021 Jan 12;5(2):ytaa513
pubmed: 33598609
Endocr Pract. 2008 Dec;14(9):1137-49
pubmed: 19158054
J Biol Chem. 2009 Nov 20;284(47):32279-87
pubmed: 19706594
Pharmacol Rev. 1999 Dec;51(4):651-90
pubmed: 10581327
J Hypertens. 2020 Aug;38(8):1443-1456
pubmed: 32412940
J Saudi Heart Assoc. 2020 Jul 15;32(2):233-235
pubmed: 33154922
J Hypertens. 2003 Sep;21(9):1703-7
pubmed: 12923403
N Engl J Med. 2005 Feb 10;352(6):539-48
pubmed: 15703419
Eur Heart J. 2008 Mar;29(6):830
pubmed: 17954493
Horm Metab Res. 2019 Jul;51(7):458-469
pubmed: 30227459
Angiology. 1994 Nov;45(11):985-9
pubmed: 7978515
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 31714582
Clin Endocrinol (Oxf). 1992 Sep;37(3):304-6
pubmed: 1424214
Front Horm Res. 2004;31:1-25
pubmed: 14674302
J Mol Cell Cardiol. 1975 Nov;7(11):807-16
pubmed: 128636
Clin Auton Res. 2018 Feb;28(1):53-65
pubmed: 28917022
Endocr Relat Cancer. 2022 Apr 22;29(5):267-272
pubmed: 35258481
Nat Rev Cardiol. 2009 Jul;6(7):482-7
pubmed: 19554007
Endocrine. 2019 Sep;65(3):483-493
pubmed: 31399912
Endocrinol Diabetes Metab Case Rep. 2017 Nov 09;2017:
pubmed: 29147570
Heart. 2013 Oct;99(19):1438-44
pubmed: 23837998
Int J Cardiol. 2017 Feb 1;228:528-536
pubmed: 27875730
Intern Med. 2015;54(18):2343-9
pubmed: 26370859
JAMA. 2002 May 15;287(19):2570-81
pubmed: 12020339
Endocr Pathol. 2022 Mar;33(1):90-114
pubmed: 35285002
J Cardiovasc Dev Dis. 2022 Feb 27;9(3):
pubmed: 35323619
J Heart Lung Transplant. 2001 Jul;20(7):773-5
pubmed: 11448809
J Mol Cell Cardiol. 2001 Jan;33(1):131-9
pubmed: 11133229
Chest. 1996 May;109(5):1394-7
pubmed: 8625697
Thromb Res. 2001 Apr 15;102(2):107-14
pubmed: 11323020
N Engl J Med. 1982 Jul 1;307(1):18-29
pubmed: 6123082
World J Cardiol. 2015 Apr 26;7(4):204-14
pubmed: 25914789
J Cardiol. 1991;21(2):203-14
pubmed: 1841907
J Hum Hypertens. 2002 Mar;16 Suppl 1:S13-7
pubmed: 11986886
Am J Hypertens. 2020 Aug 03;:
pubmed: 32744609
Am J Cardiol. 2016 Jun 1;117(11):1836-44
pubmed: 27103159
Am J Hypertens. 2023 May 21;36(6):333-340
pubmed: 36617865
Crit Care. 2008;12(3):R80
pubmed: 18564410
BMC Cardiovasc Disord. 2022 Nov 18;22(1):489
pubmed: 36401171
Biochim Biophys Acta. 1978 Jul 3;541(3):334-46
pubmed: 149563
Eur J Emerg Med. 2004 Aug;11(4):237-9
pubmed: 15249816
JACC Cardiovasc Imaging. 2020 Dec;13(12):2498-2509
pubmed: 32950457
Perfusion. 2020 May;35(1_suppl):20-28
pubmed: 32397890
Circulation. 2012 Aug 7;126(6):697-706
pubmed: 22732314
Circ Res. 2018 Aug 3;123(4):409-411
pubmed: 30355251
Am Heart J. 1981 Aug;102(2):210-21
pubmed: 7258095
Pflugers Arch. 2012 Jul;464(1):123-31
pubmed: 22328074
J Diabetes Metab Disord. 2016 Mar 17;15:6
pubmed: 26998444
Endocr Pract. 2017 Oct;23(10):1178-1192
pubmed: 28704094
Pharmacol Rev. 1972 Mar;24(1):1-29
pubmed: 4554480
J Am Coll Cardiol. 2020 Jul 28;76(4):451-464
pubmed: 32703516
Eur J Clin Invest. 1996 May;26(5):353-70
pubmed: 8796362
Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):376-82
pubmed: 11330330
JAMA Cardiol. 2021 Aug 1;6(8):974-976
pubmed: 33978674
Pharmacol Rev. 2004 Sep;56(3):331-49
pubmed: 15317907
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Curr Med Chem. 2011;18(15):2272-314
pubmed: 21517751
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414
pubmed: 35086661
Clin Cardiol. 2020 May;43(5):459-467
pubmed: 32125009
Am J Med Sci. 1971 Jul;262(1):9-13
pubmed: 5564906
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Mol Cell Biochem. 1989 May 4;87(1):85-92
pubmed: 2770715
Anesth Prog. 2015 Spring;62(1):31-9
pubmed: 25849473
Eur J Pharmacol. 2019 Jul 15;855:305-320
pubmed: 31067439
Rev Cardiovasc Med. 2021 Dec 22;22(4):1215-1228
pubmed: 34957765
Int J Mol Sci. 2020 Oct 13;21(20):
pubmed: 33066277
Endocrinol Metab Clin North Am. 2011 Jun;40(2):295-311, vii
pubmed: 21565668
J Clin Endocrinol Metab. 2007 Nov;92(11):4069-79
pubmed: 17989126
Nat Rev Dis Primers. 2019 May 9;5(1):32
pubmed: 31073128
Nephron Physiol. 2003;95(2):p19-27
pubmed: 14610323
J Heart Lung Transplant. 1992 Mar-Apr;11(2 Pt 1):363-6
pubmed: 1576142
World J Surg. 2002 Aug;26(8):1037-42
pubmed: 12192533
Int J Cardiol. 2017 Dec 15;249:319-323
pubmed: 29121733
Eur J Intern Med. 2018 May;51:68-73
pubmed: 29361475
J Clin Endocrinol Metab. 2021 May 13;106(6):e2393-e2401
pubmed: 33693908
Anesthesiology. 2008 May;108(5):959-62
pubmed: 18431133
Am J Transl Res. 2021 Sep 15;13(9):10950-10961
pubmed: 34650776
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1223-33
pubmed: 18854424
Endocr Pract. 2022 Dec;28(12):1253-1269
pubmed: 36150627
J Cardiovasc Ultrasound. 2011 Jun;19(2):76-82
pubmed: 21860721
Ann Intern Med. 2005 Jun 21;142(12 Pt 1):1026-8
pubmed: 15968023
Horm Metab Res. 2015 Aug;47(9):623-32
pubmed: 26197853